医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

American Heart Association Recommends Robot-Assisted Movement Training and Virtual Reality for Stroke Rehabilitation

2016年05月20日 PM09:00
このエントリーをはてなブックマークに追加


 

NORWELL, Mass.

For patients and therapists, believing in the benefits state-of-the-art robotic medical devices bring to the table is one thing. But having your beliefs incorporated into the official practice guidelines by associations of experts and authorities in the field is something entirely different.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160520005039/en/

Hocoma Robotic Devices (Photo: Business Wire)

Hocoma Robotic Devices (Photo: Business Wire)

Yet this is exactly what is happening. The newest Guidelines for Adult Stroke Rehabilitation and Recovery from the American Heart Association/American Stroke Association (AHA/ASA) were recently published. The following statements can be found in this important publication1:

Robot-assisted movement training, to improve motor function and mobility after stroke in combination with conventional therapy, is beneficial for patients.

Robot-assisted gait training is specifically beneficial for patients who are non-ambulatory or have low ambulatory ability early after stroke.

Combining robot-assisted gait training with virtual reality can further be beneficial for the improvement of gait.

Scientific studies back the statements the AHA/ASA are putting forth. The end goal is to provide a synopsis of best clinical practices in the rehabilitative care of adults recovering from stroke; and Hocoma fully agrees with these statements and recommendations.

Hocoma, the world leader in developing advanced medical solutions and inventor of the most-trusted robotic gait trainer, firmly believes their Lokomat helps. On one hand, patients can train more accurately and more intensively, and on the other, therapists can simplify their workflow and assessment of patient progress. And the fact that these beliefs are not only being embraced by the institutions in the field, but are also supported by more than 250 published scientific papers, is an important step forward for rehabilitation therapy.

1 References:

“Guidelines for Adult Stroke Rehabilitation and Recovery”
http://stroke.ahajournals.org/content/early/2016/05/04/STR.0000000000000098.full.pdf+html?sid=7f40d463-5fde-43bd-aa07-ea26dc5a2fb1

“First-Ever AHA/ASA Stroke Rehab Guidelines Support IRFs, Interprofessional Approaches”
http://www.apta.org/PTinMotion/News/2016/5/10/StrokeRehabPracticeGuidelines/

About Hocoma

A successful therapy begins in patients’ heads. In the firm belief that – step by step – they can reach their goals and regain quality of life.

This is what we work for at the Swiss medtech company Hocoma. With technologies and ideas that look at functional movement therapy from a completely different angle. Because they enable independent exercises and create maximum motivation. Because they challenge people to take courage and support their hopes with personal achievements.

We are committed to creating the ideal therapy. Our awarded robotic and sensor-based devices offer solutions for intensive gait therapy (Lokomat®, Andago®), functional therapy of the upper extremities (Armeo®), robotic mobilization and functional electrical stimulation in early rehabilitation (Erigo®) as well as functional movement therapy within low back pain treatment (Valedo® Therapy Concept) at home and at the clinic. They are the result of intensive research, consistent development and continuous exchange with patients, therapists and partners in research and science.

Those who see to break new grounds need to stay open to exceptional ideas. They have the potential of being exceptionally effective. This guiding principle by Hocoma founder and CEO Dr. Gery Colombo has accompanied us since our start in 2000 and is still lived and implemented by our dedicated employees around the world. Hocoma is headquartered in Volketswil near Zurich, Switzerland with subsidiaries in the USA, Singapore and Slovenia.

Product Disclaimer
All Hocoma products are medical devices and must be used in strict adherence to the User Manual; failure to do so may result in serious personal injury. It is strongly recommended that you regularly consult Hocoma’s website (www.hocoma.com/legalnotes) for the latest available information. Please contact Hocoma in case of any questions.

Use only under the supervision of qualified medical personnel. However, certain Hocoma products are marketed for home use and must be strictly used according to the recommendations of your medical care provider who is knowledgeable about your specific needs. Consult the User Manual and Hocoma’s website (www.hocoma.com/legalnotes) for appropriate product designation. Failure to obtain and follow the recommendations of your medical care provider may result in serious personal injury.

This information provides details about medical products which may not be available in all countries and may not have received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing herein should be construed as a solicitation or promotion of any product or of an indication of any specific use for any product which is not authorized by the laws and regulations of the country where the reader of this information resides.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160520005039/en/

CONTACT

Hocoma AG
Mike Fuhrmann, +41 43 444 23 65
Chief Creative
Officer
media@hocoma.com
Fax:
+41 43 444 22 01
www.hocoma.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
  • Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan
  • Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical Affairs
  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″